Publications, Pharmaceutical

Vial Stopper Compatibility: Criteria and Testing Methods

In the realm of pharmaceuticals, packaging plays a pivotal role in maintaining medication quality. The primary container, especially for injectable drugs, is crucial for preserving the medication’s integrity from production to administration. Challenges related to stopper compatibility can impact both patient safety and operational processes. Aptar Pharma developed an expertise in developing rubber formulations and components but also in testing the compatibility of these components with glass containers.

For more information on ONdrugDelivery.

Download Vial Stopper Compatibility Publication
Author(s): Dr Laure-Hélène Guillemot Dr Benjamin Brocco Edouard Pagnoud Pascal Sircoulomb
14 Jun 2024

When selecting a glass vial and rubber stopper for packaging a drug, whether it is a biotech component, vaccines or a small molecule, key compatibility criteria must be considered to ensure a perfect fit and that the drug stays protected at all times. Incompatibility issues may take the form of an excessive force required when inserting the stopper onto the vial, the stopper accidentally popping-off before having been crimped or even a loss of container closure integrity over time. All these events have the potential for putting the drug integrity at risk, which may in turn be detrimental to patients. As of the recently released USP<382>, it is now the responsibility of the drug manufacturer to demonstrate that their choice of primary packaging is fit for purpose. Choosing the right partner can help drug manufacturers derisk their operations and avoid compatibility issue that could greatly delay the commercialization of their product.

To address insertion forces, Aptar Pharma use a simple method that allow to track the force profile during the insertion process, therefore allowing for comparison of various process parameters or stoppers design. In this article, we confirm that the level of siliconization can help reduce insertion force and show that different lyophilization stopper combined with different vials can have a significantly different insertion profile.

When it comes to pop-off, our experts developed a comprehensive method that submit our vial/stoppers systems to conditions that may favor pop-off. This method allows to classify vial/stopper systems depending to their propension to resist popping-off. Once again, the result shows that these lyophilization stoppers/vial systems behave differently and that both the design of the vial and of the stoppers plays a role in preventing pop-off.

Finally, PremiumCoat® ETFE-film coated stoppers were used to test their ability to maintain long-term container closure integrity (CCI) with various vial neck design. Laser headspace analysis demonstrated that PremiumCoat® 13mm and 20mm stoppers were able to maintain CCI over time, even in a worst-case scenario where the vials are stoppered at unusually low crimping force.

This article illustrates the importance of collaborating with experts when selecting your primary packaging as incompatibilities could lead to longer validation times, operational issues but also patient adverse effect. In addition to its legacy expertise, Aptar Pharma’s is working closely with Gateway Analytical, a cGMP certified analytical expert that can performs a wide variety of test that can be used for drug filing, such as particulate testing, container closure integrity, extractables and leachables study.

For more information, read the full article and reach out to our expert.

Learn more about Aptar Pharma Expertise
in Injectable Drug Delivery

Find Out More About Injectable Drug Delivery

This Might Also Be of Interest

26 Nov 2024

Acceptability of Cyltezo® Pen Among Patients and Healthcare Professionals

Publications, Pharmaceutical, Market Insights, Product Solutions

Read More
7 Oct 2024

Beyond Probability: Choosing Deterministic Methods for Container Closure Integrity Te...

Publications, Pharmaceutical, Market Insights, Product Solutions

Read More
7 Aug 2024

Primary Packaging in the Wake of Annex1

Publications, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights, Device Innovations

Read More
25 Jul 2024

Digital Health and Oncology Innovations in Subcutaneous Administration

Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
1 2 3 14
Back To Top